Drugs / MT-3724
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02556346 | Nov 2015 → Aug 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Molecular Templates, Inc. | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02361346 | Feb 2015 → Mar 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma | Molecular Templates, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT03645395 | Apr 2019 → Mar 2021 | non-Hodgkin lymphoma | Molecular Templates, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03488251 | Aug 2018 → Mar 2021 | diffuse large B-cell lymphoma | Molecular Templates, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT02715843 | — | B-cell non-Hodgkin lymphoma | Molecular Templates, Inc. | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-3724 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02556346 ↗ |
| Route | Intravenous | “Intravenous dosing Days 1, 3, 5, 8, 10 and 12” NCT02361346 ↗ |
| Target | MS4A1 | “B-lymphocyte antigen CD20 binding agent” CHEMBL4297789 ↗ |